Tumor recurrence or regrowth was observed in seven patients at a significantly higher rate for FGFR1 mutations (50.0%, 4/8) than BRAF V600E mutations (6.3%, 2/32; p = 0.048). Here, FGFR1 is linked to neoplasm.